A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Three-arm Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)

Start Date23 Aug 2024

Sponsor / Collaborator

Kodiak Sciences, Inc.

NCT06270836

/ Active, not recruitingPhase 3

A Prospective, Randomized, Double-masked, Sham-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer in Participants With Diabetic Retinopathy (DR) - GLOW2

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.

Start Date01 May 2024

Sponsor / Collaborator

Kodiak Sciences, Inc.

NCT05066230

/ TerminatedPhase 3

A Prospective, Randomized, Double-masked, Sham-controlled, Multicenter, Two-arm Phase3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).

Start Date07 Sep 2021

Sponsor / Collaborator

Kodiak Sciences, Inc.

100 Clinical Results associated with Tarcocimab tedromer

100 Translational Medicine associated with Tarcocimab tedromer

100 Patents (Medical) associated with Tarcocimab tedromer

Literatures (Medical) associated with Tarcocimab tedromer

02 Oct 2024·Expert Opinion on Drug Metabolism & Toxicology

Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability

Review

Author: Stewart, Michael W.

INTRODUCTION:

The modern treatment of chorioretinal vascular diseases follows the recent development and rapid adoption of drugs that inhibit vascular endothelial growth factor (VEGF). All anti-VEGF drugs are delivered intravitreally, with clinical behavior, including efficacy, durability, and safety, largely determined by their pharmacokinetic properties.

AREAS COVERED:

Properties of these new drugs include additional binding targets (placental growth factor (PlGF) and angiopoietin 2 (Ang 2)), binding affinity, potency, intravitreal half-life, and increased molar dose. A PubMed search for 'pharmacokinetics of anti-VEGF drugs' was performed from 2000 to 2023. Relevant studies were reviewed and referred to in the manuscript.

EXPERT OPINION:

Early developers concentrated on improving efficacy, but since maximum efficacy with VEGF inhibition has been reached, development has pivoted to extending the duration of action. Durability strategies include inhibiting additional pathways (faricimab), increasing molar dose (abicipar, brolucizumab, faricimab, and aflibercept 8 mg), and prolonging the intravitreal half-life (abicipar and KSI-301). Recent phase 3 trials demonstrated modest improvements in durability, but failures that might be attributed to these strategies (conjugation and manufacturing processes) have occurred. Future drug development focuses on extending duration of action with implantable reservoirs (ranibizumab port delivery system), sustained release devices (tyrosine kinase inhibitors), and gene therapy.

01 Jan 2023·Ophthalmic research

Factors That Can Prolong Ocular Treatment Duration in Age-Related Macular Degeneration

Review

Author: Giani, Andrea ; Heier, Jeffery S ; Chong, Victor ; Fuchs, Holger ; Kaiser, Peter K

Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents are used to treat wet age-related macular degeneration (wAMD); however, they are associated with a considerable treatment burden and poor real-world outcomes. The molecular size and charge of anti-VEGF agents influence drug pharmacokinetics in the vitreous and peak drug efficacy. This article reviews the established and novel strategies to prolong drug action, in the vitreal cavity, and thus reduce dosing frequency. Increased ocular residency can be attained by increasing drug size as with large molecules, such as KSI-301; adding polyethylene glycol to pegcetacoplan (APL-2) or avacincaptad pegol to increase molecular size; or binding to other targets that increase molecular size, such as vitreal albumin in the case of BI-X. Faricimab is a bispecific antibody in which the fragment crystallizable portion is engineered to prolong ocular residency and reduce systemic exposure. Conversely, small VEGF-binding molecules, such as brolucizumab, can be administered at higher clinical doses, with the potential for prolonged clinical activity versus larger molecules. Other important considerations include sustained drug delivery routes, such as the ranibizumab port delivery system or subconjunctival or suprachoroidal injection. More effective and longer-lasting treatments are needed for wAMD to prolong drug action and reduce dosing frequency. Several strategies are under investigation and the prevention of vision loss in patients with AMD or other retinal diseases may be attainable in the near future.

03 Oct 2022·Expert opinion on biological therapy

Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?

Review

Author: Trong Tuong Than, Ngoc ; Hassan, Muhammad ; Akhavanrezayat, Amir ; Doan, Hien Luong ; Halim, Muhammad Sohail ; Do, Diana V ; Pham, Brandon Huy ; Chea, Sophaktra ; Matsumiya, Wataru ; Uludag, Gunay ; Nguyen, Quan Dong

INTRODUCTION:

Diabetic retinopathy (DR) is one of the most frequent microvascular complications of diabetes that can lead to blindness. Laser treatment has been the gold standard treatment for diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) for many years. Recently, the role of vascular endothelial growth factor (VEGF) has been established in the pathogenesis of DR, and the use of intravitreal anti-VEGF therapy has gained popularity for the management of DR.

AREAS COVERED:

This review includes a brief overview of the efficacy and safety of currently available (bevacizumab, ranibizumab, and aflibercept) and potential future (brolucizumab, faricimab, and KSI-301) anti-VEGF agents in patients with DR based mainly on publicly available data from phase 1, 2 and 3 clinical trials.

EXPERT OPINION:

Clinical trials investigating the efficacy of intravitreal bevacizumab, ranibizumab, and aflibercept injections demonstrated favorable functional and anatomical outcomes in patients with DME. Moreover, the use of these anti-VEGF agents showed a significant improvement in the severity of DR. Recent clinical research for future anti-VEGF molecules aims to provide higher target-protein binding affinity and prolonged therapeutic effect. Brolucizumab, faricimab, and KSI-301 are three novel anti-VEGF agents that demonstrate promising data for the management of DME and potentially DR.

News (Medical) associated with Tarcocimab tedromer

19 Dec 2025

·www.prnewswire.com

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

PALO ALTO, Calif., Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the closing of its previously announced underwritten public offering of 8,000,000 shares of its common stock, which includes 1,043,478 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $23.00 per share. The gross proceeds to Kodiak Sciences from the offering were approximately $184 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Kodiak Sciences. J.P. Morgan, Jefferies, Evercore ISI and UBS Investment Bank acted as joint book-running managers for the offering. Dr. Victor Perlroth, M.D., Chairman and CEO of Kodiak commented, "we are pleased to have successfully completed this public offering, which strengthens our financial position as we execute through important Phase 3 topline readouts for all three of our late-stage clinical assets of KSI-101, KSI-501 and tarcocimab. The transaction was thoughtfully structured, reflecting our disciplined approach to capital formation and our continued focus on long-term shareholder value." The shares described above were offered by Kodiak Sciences pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kodiak Sciences with the Securities and Exchange Commission (the "SEC") and that was declared effective by the SEC on June 2, 2023. A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available for free on the SEC's website located at . Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at [email protected] and [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, telephone: (877) 821-7388, or by emailing [email protected]; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at 888-474-0200, or by email at [email protected]; or UBS Securities LLC, Attention: Prospectus Department, UBS Investment Bank, 11 Madison Avenue, New York, New York 10010 or by email at [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Kodiak Sciences Inc. Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC® Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been at the core of Kodiak's discovery engine. We are developing a portfolio of three late-stage clinical programs. Tarcocimab and KSI-501 are being explored in two BLA-facing Phase 3 studies in the retinal vascular diseases. KSI-101 is a bispecific protein being explored in two Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions. SOURCE Kodiak Sciences Inc. 21% more press release views with Request a Demo

Phase 3

18 Dec 2025

·ir.kodiak.com

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

PALO ALTO, Calif., Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the closing of its previously announced underwritten public offering of 8,000,000 shares of its common stock, which includes 1,043,478 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $23.00 per share. The gross proceeds to Kodiak Sciences from the offering were approximately $184 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Kodiak Sciences. J.P. Morgan, Jefferies, Evercore ISI and UBS Investment Bank acted as joint book-running managers for the offering. Dr. Victor Perlroth, M.D., Chairman and CEO of Kodiak commented, "we are pleased to have successfully completed this public offering, which strengthens our financial position as we execute through important Phase 3 topline readouts for all three of our late-stage clinical assets of KSI-101, KSI-501 and tarcocimab. The transaction was thoughtfully structured, reflecting our disciplined approach to capital formation and our continued focus on long-term shareholder value." The shares described above were offered by Kodiak Sciences pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kodiak Sciences with the Securities and Exchange Commission (the "SEC") and that was declared effective by the SEC on June 2, 2023. A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available for free on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, telephone: (877) 821-7388, or by emailing prospectus_department@jefferies.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com; or UBS Securities LLC, Attention: Prospectus Department, UBS Investment Bank, 11 Madison Avenue, New York, New York 10010 or by email at ol-prospectus-request@ubs.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Kodiak Sciences Inc. Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC® Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been at the core of Kodiak's discovery engine. We are developing a portfolio of three late-stage clinical programs. Tarcocimab and KSI-501 are being explored in two BLA-facing Phase 3 studies in the retinal vascular diseases. KSI-101 is a bispecific protein being explored in two Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions. View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-announces-closing-of-184-million-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares-302646525.html SOURCE Kodiak Sciences Inc. John Borgeson, Executive Vice President and Chief Financial Officer, Tel (650) 281-0850, ir@kodiak.com

Phase 3

17 Dec 2025

·www.prnewswire.com

Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock

PALO ALTO, Calif., Dec. 16, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the pricing of an upsized underwritten public offering of 6,956,522 shares of its common stock at a price to the public of $23.00 per share. The gross proceeds to Kodiak Sciences from the offering are expected to be approximately $160 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Kodiak Sciences. The offering is expected to close on or about December 18, 2025, subject to customary closing conditions. In addition, Kodiak Sciences has granted the underwriters a 30-day option to purchase up to an additional 1,043,478 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being sold by Kodiak Sciences. J.P. Morgan, Jefferies, Evercore ISI and UBS Investment Bank are acting as joint book-running managers for the offering. The shares described above are being offered by Kodiak Sciences pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kodiak Sciences with the Securities and Exchange Commission (the "SEC") and that was declared effective by the SEC on June 2, 2023. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available for free on the SEC's website located at . A final prospectus supplement relating to the offering will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at [email protected] and [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, telephone: (877) 821-7388, or by emailing [email protected].; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at 888-474-0200, or by email at [email protected]; or UBS Securities LLC, Attention: Prospectus Department, UBS Investment Bank, 11 Madison Avenue, New York, New York 10010 or by email at [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Kodiak Sciences Inc. Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC® Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been at the core of Kodiak's discovery engine. We are developing a portfolio of three late-stage clinical programs. Tarcocimab and KSI-501 are being explored in two BLA-facing Phase 3 studies in the retinal vascular diseases. KSI-101 is a bispecific protein being explored in two Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Forward-Looking Statements This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding the completion and timing of the public offering. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to satisfaction of customary closing conditions related to the public offering. Although Kodiak Sciences believes the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risk and Kodiak can give no assurances that its expectations will prove to be correct. As a result, you should not place undue reliance on these forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Kodiak Sciences' annual report on Form 10-K for the year ended December 31, 2024 and its subsequent quarterly reports on Form 10-Q filed with the SEC, as well as in the preliminary prospectus supplement related to the proposed public offering to be filed with the SEC. The forward-looking statements contained herein speak only as of the date hereof and Kodiak Sciences undertakes no obligation to revise or update these forward-looking statements for any reason, except as required by law. Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions. SOURCE Kodiak Sciences Inc. 21% more press release views with Request a Demo

Phase 3

100 Deals associated with Tarcocimab tedromer

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nonproliferative diabetic retinopathy	Phase 3	United States	Kodiak Sciences, Inc.	07 Sep 2021
Nonproliferative diabetic retinopathy	Phase 3	Czechia	Kodiak Sciences, Inc.	07 Sep 2021
Nonproliferative diabetic retinopathy	Phase 3	Latvia	Kodiak Sciences, Inc.	07 Sep 2021
Nonproliferative diabetic retinopathy	Phase 3	Poland	Kodiak Sciences, Inc.	07 Sep 2021
Nonproliferative diabetic retinopathy	Phase 3	Puerto Rico	Kodiak Sciences, Inc.	07 Sep 2021
Nonproliferative diabetic retinopathy	Phase 3	Slovakia	Kodiak Sciences, Inc.	07 Sep 2021
Nonproliferative diabetic retinopathy	Phase 3	Spain	Kodiak Sciences, Inc.	07 Sep 2021
Diabetic macular oedema	Phase 3	United States	Kodiak Sciences, Inc.	30 Sep 2020
Diabetic macular oedema	Phase 3	Czechia	Kodiak Sciences, Inc.	30 Sep 2020
Diabetic macular oedema	Phase 3	France	Kodiak Sciences, Inc.	30 Sep 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04611152 (GLEAM, CTgov)	Phase 3	Diabetic macular oedema \| Vision, Low	460	Sham Procedure+KSI-301 (KSI-301 (Arm A))	xzgthoelow(bttaebcsqd) = qdykjmvaup idxdvcauqn (ximdjavgio, 0.83) View more	-	22 Aug 2024
				Sham Procedure+Aflibercept (Aflibercept (Arm B))	xzgthoelow(bttaebcsqd) = bvflotmtne idxdvcauqn (ximdjavgio, 0.85) View more
NCT04603937 (GLIMMER, CTgov)	Phase 3	Diabetic macular oedema \| Vision, Low	459	Sham Procedure+KSI-301 (KSI-301 (Arm A))	mzsoqpcrvr(glizqhiepy) = gjkggrwala mvvbtqqxet (marvhxwrwy, 0.80) View more	-	22 Aug 2024
				Sham Procedure+Aflibercept (Aflibercept (Arm B))	mzsoqpcrvr(glizqhiepy) = aihilzxrnc mvvbtqqxet (marvhxwrwy, 0.81) View more
NCT04049266 (DAZZLE, CTgov)	Phase 2/3	Wet age-related macular degeneration \| Wet Macular Degeneration	559	Sham Procedure+KSI-301 (KSI-301 5 mg)	snuhosshhu = vntjcvhyzb jpbsvqgaok (yfnkgxvyfz, uplosahhsi - hvqtcxqyqj) View more	-	18 Jul 2024
				Sham Procedure+Aflibercept (Aflibercept 2 mg)	snuhosshhu = cwnywqupwy jpbsvqgaok (yfnkgxvyfz, tfedhshhyc - zfsysdnytc) View more
NCT04592419 (BEACON, CTgov)	Phase 3	Retinal Vein Occlusion \| Macular Edema \| Vision, Low	568	Sham Procedure+KSI-301 (KSI-301 (Arm A))	kldwocactn(evvtwahvec) = kxxdmxsiga qzkoqhhpys (jolxovfgpj, .81) View more	-	06 Jun 2024
				Sham Procedure+Aflibercept (Aflibercept (Arm B))	kldwocactn(evvtwahvec) = bhafkdwjon qzkoqhhpys (jolxovfgpj, .79) View more
NCT04964089 (DAYLIGHT, CTgov)	Phase 3	Wet age-related macular degeneration	557	KSI-301 (KSI-301 (Treatment Group A))	txmqbenkqe(rqdkvtxqbo) = imfflmyzdn qpyxwkyhgd (jwxxzwtlpo, 0.78) View more	-	02 May 2024
				Sham Procedure+Aflibercept (Aflibercept (Treatment Group B))	txmqbenkqe(rqdkvtxqbo) = hikmspmkow qpyxwkyhgd (jwxxzwtlpo, 0.76) View more
NCT05066230 (GLOW, PRNewswire) Manual	Phase 3	Nonproliferative diabetic retinopathy	253	tarcocimab tedromer	xweunxrxpv(usefrjojsf) = mjywkcvkoj cacpdkaeal (ymkxujmjbn ) View more	Positive	06 Nov 2023
				placebo	xweunxrxpv(usefrjojsf) = vsywxjagid cacpdkaeal (ymkxujmjbn ) View more
NCT04592419 (BEACON, Corporate Publications) Manual	Phase 3	Retinal Vein Occlusion	568	tarcocimab tedromer	aeufvyurve(siojdcaitk): P-Value = 0.0004 View more	Non-inferior	08 Aug 2022
				Aflibercept
NCT04049266 (DAZZLE, Corporate Publications) Manual	Phase 2/3	Wet age-related macular degeneration First line	559	Tarcocimab tedromer	cempkgiliw(twvqykkcsj) = sqleojwoac ejptixrwyo (ueknczkvkb ) View more	Negative	23 Feb 2022
				Aflibercept	cempkgiliw(twvqykkcsj) = zangifprzs ejptixrwyo (ueknczkvkb ) View more
NCT03790852 (ARVO2020)	Phase 1	Diabetic macular oedema \| Retinal Vein Occlusion \| Wet age-related macular degeneration	109	KSI-301 2.5 mg	umdkfdroed(lndibojmgl) = no drug-related adverse events after 338 doses mfneqwpnjr (uaernszbzc ) View more	-	01 Jun 2020
				KSI-301 5 mg

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis